Green Cross Wellbeing Corporation

What Green Cross Wellbeing Corporation does

Green Cross Wellbeing Corporation (GC녹십자웰빙) is a Seoul-headquartered, private Korean healthcare company operating as a subsidiary of the GC Group (GC녹십자홀딩스). Founded in 2016, the company focuses on personalized nutrition therapy, building its business around four product pillars: specialty pharmaceuticals (led by the placental injection 라인넥주/Lactin, which holds #1 share in the domestic nutritional injection market), health functional foods (Dr.PNT for hospital/clinic channel, Dr.Pack for customized consumer products, and general retail health functional foods), cosmetics under the BOONJA brand leveraging proprietary NK cell culture fluid technology containing 74 bioactive factors, and Class II medical devices such as Dexian MD Cream.

The underlying technology platform rests on proprietary placental hydrolysis processing (the only domestic facility of its kind, with API DMF registration), NK cell culture technology, age- and gender-segmented probiotic R&D based on gut microbiome research, and standardized natural-product ingredient development. Manufacturing is vertically integrated across three sites: the Eumseong Plant (placental extract specialist with virus inspection and traceability), the Seongnam Plant (FGMP-certified health functional food manufacturing), and a newly built Innovation Plant with 10,000평 of land, 5,600평 of building area, and annual capacity of 27 million vials and 36 million ampoules. The pipeline includes new injectable drugs (including a high-dose IV 라인넥 Phase 3 program), novel drug development for cancer cachexia, and the rare disease asset GC1130A for Sanfilippo syndrome type A co-developed with Nobel Pharma.

Revenue is generated through a sales-led model targeting three customer segments: hospitals and clinics (B2B sales of Dr.PNT and prescription injectables), general consumers (B2C e-commerce via the Dr.PNT mall and general retail distribution), and medical device patients. Pricing details are not publicly disclosed. Disclosed 2023 revenue reached 120,535 백만원 (≈120.5 billion KRW, ~$90M), up from 109,729 백만원 in 2022 and 90,968 백만원 in 2021, with 2023 operating income of 10,457 백만원 and net income of 6,748 백만원. Geographic expansion is in early stages, with a strategic 2024 partnership with China Resources Pharmaceutical Group opening China distribution for Albumin, Greenjet F, and the company's hyaluronic acid fillers.

Name

Green Cross Wellbeing Corporation

Legal name

GREEN CROSS WellBeing

Website

https://greencrosswb.com

Company type

Private

Founded year

2016

Operating status

Operating

Short description

Green Cross Wellbeing Corporation is a Korean GC Group subsidiary that develops and sells personalized nutrition products — including the #1 domestic placental injection 라인넥주, hospital-channel health functional foods (Dr.PNT), NK cell-based cosmetics (BOONJA), and medical devices — serving hospitals, clinics, and consumers in South Korea and China.

Ownership category

akta.pro rank

Product category

Personalized Nutrition Solutions & Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Food (Health) Supplement Retailers (456191)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Miscellaneous Food Preparations & Kindred Products (2090)

akta.pro primary industry

Healthy Aging & Cognitive Support Supplements (CRADAGAM)

akta.pro secondary industry

Fortification Ingredients (Vitamins, Minerals, Nutrient Premixes) (CRADAOAM)

Keywords

• Personalized nutrition solutions
• Placental pharmaceuticals
• Health functional foods
• Probiotic development
• Medical device creams

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Specialty Pharmaceuticals: Sales of prescription pharmaceutical products including placental injection Linec (라이넥주), vitamin injections, and other injectable medications. The company holds #1 market share in the domestic nutritional injection market.
2. Health Functional Foods: Production and sales of health functional foods including Dr.PNT for medical institutions and customized health functional foods through Dr.Pack service, as well as general consumer products
3. Cosmetics (BOONJA): Skincare and aesthetic products developed with proprietary NK cell culture technology
4. Medical Devices: Sales of medical device type moisturizing creams such as Dexian MD Cream
5. B2B Solutions: Business-to-business personalized nutrition solutions and OEM/customized manufacturing services

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Green Cross Wellbeing Corporation (GC녹십자웰빙) develops and manufactures personalized nutrition solutions, including specialty pharmaceuticals (placental injection Linec/Lactin for liver function, vitamin injections), hospital/clinic-channel and consumer health functional foods (Dr. PNT, Dr. Pack, general age/function-specific products), cosmetics (BOONJA brand with NK cell culture technology), and Class II medical devices (Dexian MD Cream). The company holds #1 market share in the domestic Korean nutritional injection market.

Product overview

Green Cross Wellbeing Corporation (GC녹십자웰빙) is a diversified healthcare company operating a multi-category portfolio consisting of specialty pharmaceuticals, health functional foods, cosmetics, and personalized nutrition solutions. The core platform centers on personalized nutrition solutions, integrating products across specialty pharmaceuticals (라이넥주/Lactin for liver function), health functional foods distributed via hospital/clinic channels (Dr. PNT) and general retail (general health functional foods, Dr. Pack), and cosmetics (BOONJA featuring NK cell technology). The company positions itself as a leader in customized nutrition, combining proprietary research capabilities in probiotics, individually recognized functional ingredients, and pharmaceutical development with manufacturing infrastructure including three facilities: placenta-based pharmaceutical plant (Eumseong), health functional food plant (Seongnam), and an innovation plant capable of producing 27 million vials and 36 million ampules annually.

Differentiator

Problem solved

Functional benefit

Brands

• BOONJA: Proprietary cosmetics brand leveraging NK (Natural Killer) cell culture fluid containing 74 factors to awaken skin's inherent beauty, developed using GC녹십자웰빙's own technology.
• Dr. PNT
• Dr.Pack
• 프로비던스 (Providence)

Products and services

• Linec (라이넥주) / Lactin placental injection

Quantifiable outcome

• Linec cumulative production of 83 million+ doses since 2005
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• CR Pharmaceutical Group (화륜 제약그룹 / China Resources Pharmaceutical Group)coreStrategic or Co-development Partner · 17 July 2024Strategic partnership for China market entry. GC sold its Hong Kong subsidiary Green Cross HK Holdings Limited to CR Boya Bio-pharmaceutical for 1.82 billion yuan (approximately 350 billion KRW). Distribution agreements for GC녹십자 products including Albumin and Greenjet F, as well as GC녹십자웰빙 hyaluronic acid fillers in China. Includes strategic cooperation framework agreement for technology cooperation, licensing, joint R&D, technology transfer, and CDMO services.
• Nobel Pharma (노벨파마)coreStrategic or Co-development Partner · 11 July 2024Joint development of MPS IIIA (Sanfilippo syndrome type A) treatment drug GC1130A. Received IND approval from both FDA (May 2024) and MFDS (July 2024) for Phase 1 clinical trials. GC1130A applies high-concentration protein formulation technology for intracerebroventricular injection to treat the disease.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Hanmi Pharmaceutical: Leading Korean R&D-driven pharmaceutical company with OTC and consumer health offerings, serving similar hospital/clinic channels as GC Wellbeing with substantially larger scale.
• CJ CheilJedang: Major Korean food/health conglomerate with health functional food and supplement lines via CJ Welldare - broader-than-GC-Wellbeing but operating in adjacent Korean consumer health categories.
• Dong-A Pharmaceutical: One of Korea's largest pharmaceutical groups operating across prescription pharma, OTC consumer health, and health functional foods - addressing overlapping customer segments (clinics, hospitals, retail) with broader category coverage than GC Wellbeing.
• Yuhan Corporation: Major Korean pharmaceutical conglomerate with prescription products, consumer health supplements, and OTC brands, comparable in scale and channel reach across the Korean healthcare ecosystem.

Direct peers

• AmorePacific: Korean cosmetics leader with biotech-backed skincare (e.g., Sulwhasoo, Amorepacific) - directly comparable as a Korean player developing proprietary bio-cosmetic technologies against BOONJA's NK cell culture positioning.
• Yakult Honsha: Global probiotic beverage and supplement leader with a singular focus on microbiome-based health - the closest international comparable to GC Wellbeing's Providence probiotic brand across lifecycle stages.
• Kolmar Korea: Korea's leading health functional food and cosmetics contract manufacturer with consumer brands - directly comparable OEM/CDMO and branded capabilities that compete with GC Wellbeing's manufacturing and health functional food lines.
• BioGaia: Swedish probiotics specialist with lifecycle-stage formulations (pediatric to adult), the international benchmark for clinically-validated probiotic brands comparable to GC Wellbeing's Providence product line.
• Kwangdong Pharmaceutical: Korean pharmaceutical and health functional food manufacturer with a similarly diversified portfolio across prescription drugs, OTC supplements, and consumer health products, directly competing with GC Wellbeing's Dr.PNT and Dr.Pack offerings in domestic channels.

Emerging players

• Care/of (Bayer): US-based personalized vitamin/subscription nutrition brand - a leading international benchmark for the personalized nutrition model that GC Wellbeing is pursuing through Dr.Pack and Providence.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Green Cross Wellbeing Corporation